Intec Pharma Ltd (NASDAQ:NTEC) Given Average Recommendation of “Hold” by Analysts

Shares of Intec Pharma Ltd (NASDAQ:NTEC) have been assigned an average recommendation of “Hold” from the eight research firms that are covering the company, MarketBeat reports. Seven research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $1.00.

A number of equities research analysts have recently commented on the stock. Roth Capital cut shares of Intec Pharma from a “buy” rating to a “neutral” rating and cut their price target for the company from $10.00 to $1.00 in a report on Friday, October 11th. Zacks Investment Research lowered shares of Intec Pharma from a “buy” rating to a “hold” rating in a report on Thursday. HC Wainwright restated a “hold” rating on shares of Intec Pharma in a report on Monday. LADENBURG THALM/SH SH reaffirmed a “hold” rating on shares of Intec Pharma in a research report on Monday, August 12th. Finally, ValuEngine downgraded Intec Pharma from a “buy” rating to a “hold” rating in a research note on Friday, November 1st.

Intec Pharma stock remained flat at $$0.61 during mid-day trading on Friday. 317,578 shares of the company were exchanged, compared to its average volume of 917,404. Intec Pharma has a 52 week low of $0.41 and a 52 week high of $9.25. The company’s 50 day moving average price is $0.62 and its 200-day moving average price is $1.93. The firm has a market cap of $16.29 million, a P/E ratio of -0.44 and a beta of -0.13.

Intec Pharma (NASDAQ:NTEC) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.10). As a group, sell-side analysts predict that Intec Pharma will post -0.92 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Taylor Frigon Capital Management LLC bought a new position in Intec Pharma during the 3rd quarter valued at about $302,000. River & Mercantile Asset Management LLP purchased a new position in shares of Intec Pharma during the second quarter valued at approximately $1,230,000. Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Intec Pharma by 25.9% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 729,193 shares of the biotechnology company’s stock valued at $3,165,000 after purchasing an additional 150,000 shares during the last quarter. Renaissance Technologies LLC purchased a new position in shares of Intec Pharma during the second quarter valued at approximately $593,000. Finally, Virtu Financial LLC bought a new position in Intec Pharma during the third quarter valued at approximately $96,000. Institutional investors own 17.21% of the company’s stock.

Intec Pharma Company Profile

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Read More: Asset Allocation and Your Retirement

Analyst Recommendations for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit